drugset / Trial / NCT00320450
SB-681323 In Subjects With Rheumatoid Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this research is to find out how effective and safe SB-681323 will be in the treatment of RA when it is added to standard anti-rheumatic treatments.
Timeline
- Start
- 2005-11
- Primary completion
- 2006-10
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dilmapimod | Small molecule | 7.5 mg | — |